News

Breakthrough Drug Approval Signals Great Advances in Lung Cancer Treatment

IASLC 

Contact: Jeff Wolf                                                                                                  Becky Bunn                                          
IASLC Director of Communications                                                                   IASLC Projects Specialist                    
Jeff.Wolf@IASLC.org | 720-325-2952                                                             Becky.Bunn@IASLC.org | 720-325-2946       

 

Breakthrough Drug Approval Signals Great Advances in Lung Cancer Treatment
IASLC Applauds Move to Accelerate Approval in U.S.

DENVER, Colo. – The International Association for the Study of Lung Cancer (IASLC) says the move by the U.S. Food and Drug Administration (FDA) to grant accelerated approval for a cutting-edge lung cancer treatment is a positive step forward that may help many patients improve their survival.

In early October, the FDA granted accelerated approval for pembrolizumab (Keytruda) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease continued to progress after other treatments, and with tumors that have a protein called PD-L1.

“This is great news for patients and physicians working together on lung cancer treatment plans,” said Dr. Fred R. Hirsch, Professor of Medicine and Pathology at the University of Colorado Cancer Center and School of Medicine and CEO of the IASLC. “This drug represents important progress in the lung cancer treatment that can extend lifespans and make a real difference.”

Personalized medicine - treating patients with therapies based on the molecular characteristics of a patient’s tumor – can add many months or years for those patients whose tumors harbor specific abnormalities. Doctors then treat patients with therapies specifically targeting these abnormalities. Therefore, molecular characterization (“testing”) of the patient’s tumor is crucial for the right choice of therapy.

“These days, we are discovering several new active drugs for patients with lung cancer and we are getting closer to finding ways to make lung cancer a treatable, chronic disease.” Dr. Hirsch said.

Lung cancer is the leading cause of cancer related deaths throughout the world. Lung cancer causes more than 1.6 million deaths globally every year; more deaths than breast, colon and prostate cancers combined. Doctors diagnose the majority of lung cancer cases (~60 percent) after the disease has already spread to distant areas, which makes the disease more difficult to treat.  However, for the first time in many decades, specific targeted therapies and immunotherapy treatment are providing hope to the many lung cancer patients for significantly increased and better life perspective.

For more information about pembrolizumab, visit the FDA’s website.

 

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 4,000 lung cancer specialists in over 90 countries. Visit www.iaslc.org for more information.

 

###

October 8, 2015